BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance).

ABSTRACT:

Objective

To evaluate the prognostic significance of detectable circulating cell-free DNA (cfDNA) BRAF V600E/K mutations in patients with advanced melanoma enrolled in a clinical trial without BRAF-targeted therapy.

Patients and methods

BRAF V600E/K mutation status was determined on archived tissue and pretreatment stored plasma from 149 patients with unresectable stage IV melanoma who were enrolled between May 5, 2010 and May 2, 2014 in the North Central Cancer Treatment Group/Alliance N0879 randomized phase 2 clinical trial. Results were reported as presence or absence of cfDNA BRAF V600E/K detection of assay vs tissue. Progression-free survival (PFS) and overall survival (OS) were assessed for patients with and without detectable BRAF mu

SUBMITTER: Slostad JA 

PROVIDER: S-EPMC8526905 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature